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ABSTRACT
Fecal microbiota transplant (FMT) is a powerful tool used to connect changes in gut microbial 
composition with a variety of disease states and pathologies. While FMT enables potential causal 
relationships to be identified, the experimental details reported in preclinical FMT protocols are 
highly inconsistent and/or incomplete. This limitation reflects a current lack of authoritative 
guidance on reporting standards that would facilitate replication efforts and ultimately reproduci-
ble science. We therefore systematically reviewed all FMT protocols used in mouse models with the 
goal of formulating recommendations on the reporting of preclinical FMT protocols. Search 
strategies were applied across three databases (PubMed, EMBASE, and Ovid Medline) until 
June 30, 2020. Data related to donor attributes, stool collection, processing/storage, recipient 
preparation, administration, and quality control were extracted. A total of 1753 papers were 
identified, with 241 identified for data extraction and analysis. Of the papers included, 92.5% 
reported a positive outcome with FMT intervention. However, the vast majority of studies failed 
to address core methodological aspects including the use of anaerobic conditions (91.7% of papers 
lacked information), storage (49.4%), homogenization (33.6%), concentration (31.5%), volume 
(19.9%) and administration route (5.3%). To address these reporting limitations, we developed 
theGuidelines for Reporting Animal Fecal Transplant (GRAFT) that guide reporting standards for 
preclinical FMT. The GRAFT recommendations will enable robust reporting of preclinical FMT 
design, and facilitate high-quality peer review, improving the rigor and translation of knowledge 
gained through preclinical FMT studies.
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The collection of microorganisms in the gastroin-
testinal tract, termed the gut microbiota, is growing 
in appreciation for its dynamic regulation of host 
function and disease. While large-scale sequencing 
studies have provided unprecedented insight into 
the range of conditions associated with the micro-
biome, they are unable to provide conclusive evi-
dence for how the microbiota causally contributes 
to disease and how it can be exploited to modify 
disease risk or progression.1
Fecal microbiota transplantation (FMT) is 
a powerful technique in which the microbial com-
munity is transferred from a donor to a recipient 
host, transferring a unique microbial enterotype to 
prevent, treat or (preclinically) induce disease, or 
modulate host physiology. Clinically, FMT is 
now second-line therapy for antibiotic-resistant 
Clostridioides difficile (C. difficile) and its scope is 
expanding.2 Indeed, there is a growing list of emer-
ging indications under investigation in a variety of 
preclinical models and pilot cohorts.3,4 In addition 
to its therapeutic application, preclinical FMT is 
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increasingly used to dissect causal microbiota- 
dependent mechanisms and understand how 
unique microbial profiles dictate disease risk.
Although a powerful technique, the regulatory 
landscape for clinical use of FMT is challenging, 
largely due to the ambiguities regarding its classifi-
cation (i.e. biological product equivalent to blood 
or organ versus drug).5 Despite this, there are clear 
recommendations and guidelines for FMT prepara-
tion, administration, and quality control when used 
in human recipients.6 In contrast, preclinical FMT 
protocols vary enormously, as recently 
highlighted,7 with little to no recommendations 
on best practice and reporting standards. This pro-
foundly hinders the ability to interpret and repli-
cate preclinical FMT studies and the inconsistent 
application of experimental approaches compro-
mises clinical translation.
The need for better guidance of preclinical FMT 
protocols is underscored by the additional layers of 
complexity that are introduced in a preclinical set-
ting. For example, experimental design, prepara-
tion and administration are complicated by the 
coprophagic nature of rodents. While some studies 
have exploited this behavior (co-housing to induce 
microbial transfer),8 there is significant variability 
in how this technique is applied and the omission 
of key methodological detail hinders experimental 
replication, thus undermining subsequent 
translation.9 Similarly, while bowel preparation is 
recommended for colonoscopically administered 
FMT in humans, the necessity for an appropriate 
equivalent in recipient rodents remains unclear.
Germ-free (GF, i.e. those without any resident 
microorganisms) mice have often been used as 
recipients in FMT models, as their lack of existing 
gut microbiota represents a highly effective ‘take- 
up’ of the donor FMT. However, as previously 
highlighted,10 barriers related to cost and logistics 
have prevented widespread use of this model, and 
concerns regarding how closely they mimic normal 
immune development have plagued interpretation 
of results generated.11 Therefore, antibiotic- 
induced depletion of the microbiota has become 
common practice to ablate the microbial commu-
nity of the gut. However, there are vast differences 
in the antibiotic treatment specifications used in 
animal models, including FMT. These include 
type, dose and duration, which can introduce 
significant variability in ablative capacity, with per-
sisting pathogens confounding results (for 
a comprehensive review of this topic, please see 
Gheorghe et al.12).
While antibiotic treatment represents 
a particularly common area of variability, in reality, 
each step of preclinical FMT protocols can intro-
duce bias. This was recently highlighted by Walter 
et al. (2020) who identified that 95% of preclinical 
FMT studies reported successful transfer of the 
clinical phenotype to the recipient rodent – 
a figure deemed implausible by the authors.13 
While these findings also reflect publication biases, 
they underscore the need to advocate for standar-
dization of approaches for preclinical FMT when 
inferring causality to prevent unrealistic expecta-
tions that may undermine the credibility of micro-
biome science and delay its translation.
A key element of this enhanced rigor must be 
clarity in the methodological standards and report-
ing to improve consistency and transparency 
within the field, both of which will strengthen the 
reproducibility of findings. As such, we systemati-
cally reviewed published literature on preclinical 
FMT use in mice to provide a snapshot of current 
reporting patterns and, in collaboration with key 
microbiome research sites and networks, developed 




Of 1753 screened studies, a total of 241 were 
included. One thousand one hundred and ninety- 
six were screened via title and abstract, with 728 
excluded as not relevant. Four hundred and sixty- 
eight full-text articles were assessed. Two hundred 
and twenty-seven were excluded at the full-text 
stage (Figure 1).
Study Characteristics
We studied papers evaluating FMT across 
a range of indications (Figure 2a). The most com-
mon area of investigation was metabolism/meta-
bolic disease, accounting for 23.7% of all papers 
reviewed. Other areas of investigation included 
infectious diseases (15.4%), gastroenterology/ 
inflammatory bowel disease (14.9%) and cogni-
tion/behavior/affect disorders (6.6%).
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Studies ranged in the sample size used per experi-
mental group (median [range]:8 [2–70]), reflecting 
varying power requirements for specific models. 
Disappointingly, 21.4% of the eligible studies did 
not clearly state the sample size of the recipient 
group. While the sample size for the donor FMT 
group was not extracted in our analysis due to low 
levels of reporting, it is also important to acknowl-
edge that this should also be clearly reported along-
side information on whether FMT contents are 
pooled across multiple donor samples. Donor sam-
ple size is particularly pertinent in the use of human 
donors, as recently outlined by Gheorghe et al. with 
the use of a single donor considered N = 112.
Data extracted
Collection, processing and storage
There are several aspects of FMT preparation that 
must be acknowledged and highly protocolized for 
rigorous results: collection of donor stool, 
processing and storage. The vast majority of papers 
used fecal pellets to prepare the FMT product 
(73.0%; Figure 2b), with the remaining using cecal 
(12.9%) contents or other gastrointestinal products 
(e.g. duodenal aspirates and feces, mucosal scrap-
ings, small and large intestinal contents collected 
from a culled mouse). A range of preparation tech-
niques were used to produce the FMT, including 
filtrates, supernatants, and slurries. In the papers 
reviewed, a fecal slurry was most commonly used 
(50.6%; Figure 2c), with supernatants and filtered 
products used in 33.6% and 9.9% of papers, 
respectively.
In any FMT preparation, the vehicle/diluent 
must be carefully considered. In the studies 
included for analysis, phosphate buffered saline 
(PBS) was the most common solution (80.5%; 
Figure 2d), with a small number of studies includ-
ing additives to the PBS (glycerol, cysteine hydro-
chloride) to improve microbial viability. The 
concentration of cysteine-hydrochloride was con-
sistent across all studies (0.05%), whilst the 
Figure 1. PRISMA flow chart for identification and selection of eligible studies.
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concentration of glycerol ranged from 5% to 50%. 
While only 7.5% of studies failed to report the 
vehicle solution used for FMT preparation, 91.7% 
of studies failed to report whether this solution was 
reduced (i.e. de-oxygenated) or if the FMT was 
prepared under anaerobic conditions.
The high number of studies that failed to expli-
citly state whether FMT was prepared under anae-
robic conditions is concerning as it has been 
reported that FMT prepared under aerobic condi-
tions profoundly decreases microbial viability, 
altering microbial metabolite synthesis and abun-
dance of many anaerobic commensals.14–16 
Similarly, the way in which the fecal/cecal con-
tents were processed was poorly reported, with 
33.6% of studies failing to report on homogeniza-
tion. This methodological step was generally 
reported with limited detail, using broad terminol-
ogy such as “dissolved”, “mixed” or “suspended” 
(Figure 2e), with only 12% of studies providing 
sufficient detail for replication of the homogeniza-
tion step. A similar observation was made for 
filtration methods used when preparing superna-
tants or bacterial preparations, with 31.5% of stu-
dies failing to report on any filtration or “clean 
up” steps. For clarity and replication, manual fil-
tration should be defined by the size of the strainer 
used and centrifugation defined using standard 
metrics (x g, min, oC).
Once processed, the final FMT product can and 
should be quantified in terms of its concentration. 
Strikingly, 31.5% of studies failed to report 
a concentration, with the remaining studies using 
a wide range of units, including mg/ml (63.0%), 
pellets/ml (13.9%) and CFU/ml (9.6%). While we 
do not intend on recommending a specific unit to 
define concentration, it is critical that the final FMT 
product is defined in a standard unit of 
Figure 2. Key data extracted from N = 241 studies included for analysis.
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measurement that can be replicated by others. 
Studies reporting pellets (but no volume) or milli-
liters (but no weight) were deemed irreproducible.
The final FMT product can then be used imme-
diately (fresh) or stored and used at a later date. As 
such, clarity on this methodological detail must be 
clearly provided particularly in light of the evidence 
that shows storage conditions impact microbial pre-
servation and viability.17,18 Of the papers included 
in our analysis, 31.9% administered freshly prepared 
(i.e. not stored) FMT. A number of papers (18.7%) 
noted that the FMT product was frozen (−20°C and 
−80°C) prior to administration; however, close to 
half of the papers (49.4%) did not report any meth-
odological detail on storage conditions (figure 2f).
Recipient preparation and FMT administration
Once the FMT has been prepared, there are 
many considerations in its administration related 
to both the product itself and the recipient, 
including typical reporting standards related to 
husbandry. Of the studies included, 30.2% failed 
to provide any detail on animal housing condi-
tions (i.e. single vs co-housed). Given the copro-
phagic nature of rodents, it is critical that this be 
clearly reported in all studies in which FMT is 
used to acknowledge/exclude potential con-
founding impacts.
We also investigated how, if at all, recipient mice 
were prepared for FMT. As suggested previously,19 
there is some evidence that bowel lavage or cleans-
ing could improve FMT efficacy; however, these 
remain speculative and not widely recommended. 
Accordingly, very few studies (N = 3) included in 
our analysis reported bowel preparation procedures 
in recipient mice. One study fasted mice the night 
prior to FMT administration and two studies pro-
vided PEG3350 as a laxative beforehand. 
Antibiotic-induced depletion was used in 60.5% of 
studies, most commonly administered in drinking 
water (61.4%) for a median of 14 days [1–91 range] 
(Figure 3a). The most common combination was 
a cocktail of ampicillin, neomycin, vancomycin, 
and metronidazole (ANVM; Table S1).
While antibiotic-induced depletion has, to date, 
been an area of critical methodological considera-
tion in optimal FMT administration, it remains an 
area of contentious debate. In fact, increasing evi-
dence suggests that antibiotic depletion may not be 
necessary for FMT uptake; albeit the evidence is 
conflicting. While Ji et al. (2017) reported great 
Figure 3. Distribution of objective FMT-related variables across N = 241 studies included. A) days of antibiotic exposure, B) volume of 
FMT administered, C) number of FMT doses administered. All data are shown as individual studies with median/range. Median: A = 14, 
B = 200, C = 5.
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FMT durability with antibiotic depletion compared 
to either a MoviPrep bowel cleanse or no 
pretreatment,20 others have shown no difference. 
For example, Freitag et al. (2019) showed that pre- 
treatment with antibiotics did not improve the 
overall engraftment of the donor microbiome, and 
only improved the engraftment of a small number 
of taxa.19 While Ji et al. (2017, not included in this 
review) utilized a human donor microbiome, 
Freitag et al. (2019) used a mouse donor micro-
biome, suggesting that antibiotic administration 
may be useful in improving FMT engraftment 
across the species barrier. While we do not intend 
on recommending the use of antibiotics in FMT 
studies, these findings highlight the need to clearly 
describe all pre-treatments used to prepare the 
recipient for FMT.
FMT administration can be achieved via oral or 
rectal routes. It has been previously speculated that 
as oral gavage inoculum needs to pass through the 
acidic stomach environment, rectal administration 
may be more efficient.21 However, a previous study 
of FMT in mice showed that specific pathogen-free 
mice treated with antibiotics and then orally or 
rectally inoculated with donor mice gut microbiota 
had no differences in microbial community after 
inoculation.22 As such, while rectal administration 
is preferable in efficacy and safety outcomes for 
clinical FMT use, oral gavage is often selected in 
mouse studies, presumably due to convenience.23 
In line with these findings, the overwhelming 
majority of studies included in our analysis opted 
for oral administration (90.4%; Figure 2g) and only 
a small number used rectal administration (2.9%). 
Three studies reported alternative methods of 
administration, including directly pipetting into 
the oropharynx,24 which can be used when oral 
gavage is not permitted (note that other methods 
including co-housing and vertical transfer (genera-
tional transfer between mothers and pups) were 
excluded). The route of administration was the 
most consistently reported aspect of FMT metho-
dology; only 5.3% of papers either did not report or 
did not clearly state how their FMT product was 
administered.
Administration volume is also critical to FMT 
replication, with our analyses identifying a large 
range of volumes administered to recipient mice 
(median[range]: 200 µl [25–1000]; Figure 3b). 
Volume was not reported in 19.9% of studies 
included in our analysis. Similarly, the frequency 
of FMT (or absolute number of treatments) was not 
reported in 13.2% of studies. Of the studies that did 
report this metric, there was again a significant 
range (1–120 treatments) with a median of 5 FMT 
treatments (Figure 3c).
In administering the FMT, adequate control pro-
cedures must be implemented to account for the 
impact of the procedure. This can be achieved by 
administering an autologous FMT or one prepared 
using sham/control animals. Alternatively, the vehi-
cle solution can be administered. Forty percent of 
papers included in our analysis failed to use 
a control arm or report on what their control ani-
mals received. Of the studies that did report this 
detail, 56% used FMT prepared from sham/control 
animals and 34% used the vehicle solution.
Quality control and uptake confirmation/durability
The success of FMT relies on a number of complex 
and interacting factors, but central to its general 
efficacy is its viability (after collection and proces-
sing) and uptake (“durability”).
We defined quality control (QC) as analysis of the 
FMT product before administration to the recipient, 
i.e. to identify the presence of potential pathogens and 
confirm viability of the product. No information 
regarding quality control was reported in 88.4% of 
studies. Of the few studies that did include QC, 16S 
rRNA sequencing was the most commonly used tech-
nique (53.6%) followed by standard culture (32.1%). 
Given the inability of 16S rRNA sequencing to deter-
mine the viability of the microbial community, these 
findings underscore the need to implement standar-
dized preclinical FMT guidelines to ensure appropri-
ate QC is incorporated at project inception.
Confirming uptake of the FMT is also critical to 
its efficacy. Le Roy et al. (2018) defined the dur-
ability of the FMT procedure as: 1. Establishment of 
high levels of bacterial taxa from the inoculum in 
recipients, 2. Relative abundance of bacterial taxa as 
similar as possible in the inoculum and recipients, 
and 3. The removal of a high amount of endogen-
ous bacterial taxa in non-GF recipients.7 This can 
be determined by microbial analysis of the FMT 
inoculum, and gut microbial contents of the reci-
pient both before and after FMT occurs.
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Overall, explicit reference to durability assess-
ment was lacking with microbial analyses often 
reported in the study but rarely compared between 
the FMT donor, product, and recipient. In fact, 
22.1% of papers did not report or did not confirm 
uptake of the FMT in any way. Of the papers that 
did report, 16S rRNA sequencing was the primary 
method (86.9%) with other studies reporting cul-
ture- (6.0%) or PCR-based approaches (4.3%).
Reproducibility and rigor
A recent systematic review searched scientific lit-
erature for studies suggesting a causal relationship 
between an altered human microbiome and disease 
or physiological condition.13 Of the papers meeting 
the inclusion criteria, all but two (95%), suggested 
that fecal transfer from diseased donors resulted in 
a disease phenotype. Due to the wide range and 
complexity of pathologies studied in these papers, 
the authors suggested that the causal claims seem 
unlikely across this wide range. Similarly, in our 
study, we found that 92.5% of papers showed that 
FMT had an effect. This may reflect publication 
bias – a tendency to favor positive findings for 
publication, or it could also suggest that the intro-
duction of any new complex combination of 
microbes via FMT may cause a protective immune 
response in the gut, that manifests as a change in 
symptoms or disease severity. Thus demonstrating 
the wide variety of potential uses for FMT. 
Regardless, as suggested by Walter et al. (2020), 
microbiome science would benefit from increased 
rigor and critique.13 A key part of this scientific 
rigor is transparent and reproducible 
methodology.13,25
Throughout our analysis, we found that many 
methods described in published manuscripts did 
not have sufficient detail to be completely replicated. 
Therefore, we developed a reproducibility index con-
taining 10 key aspects of FMT methodology and 
assigned a score from 0 to 1 for each variable, where 
0 = not reported, 0.5 = reported with insufficient 
detail and 1 = reported with sufficient detail for 
replication (Figure 4). The median total value of this 
index was 6.5, with 23.6% of papers gaining a total 
value of 5 or more. Two papers had a reproducibility 
index of 9.5/10 in our review, the highest observed. 
The first paper (Krisko et al., 2020) paid particular 
detail to the preparation of donor mice, and the use of 
anaerobic conditions in FMT preparation.26 
The second paper (Zhou et al., 2019) provided good 
detail about the amount, and concentration of the 
administered FMT product.27 In addition, Foligne 
et al. clearly outlined group numbers of both donors 
and recipient mice.28 While this measure provides an 
objective assessment of the level of detail in reporting, 
it is important to recognize that this should be inter-
preted with caution as the index is not validated. 
Thorough review of the literature yielded no appro-
priate method for assessing methodological reporting 
in this way, and as such, the reproducibility index was 
developed specifically for this study.
The GRAFT recommendations and future steps
Our systematic review revealed an overall lack of 
clarity in the reporting of FMT methods. In almost 
all variables we investigated, there was not only a lack 
of consistency in FMT protocols, but also a lack of 
clarity and detail in methodological reporting. For 
example, for FMT concentration, as well as the actual 
concentration ranging widely, 7 different units were 
used to report this key step in FMT preparation. 
These findings point to a lack of authoritative gui-
dance on preclinical FMT studies for both authors 
and reviewers.
Due to the low level of detail found in many 
papers and the low mean score from our reprodu-
cibility index scoring, we suggest that a minimum 
set of reporting standards for preclinical FMT stu-
dies would be useful. As such, we present here the 
GRAFT (Guidelines for Reporting on Animal Fecal 
Transplantation) recommendations (Table 1, 
Figure 5) along with a simple checklist (File S1) 
that can be used at project inception/design, manu-
script preparation, and review. By providing these 
recommendations, we hope to increase the trans-
parency and reproducibility of preclinical FMT 
procedures, thus elevating their translational 
strength. While our systematic review intentionally 
restricted our search to studies with mice, we argue 
that, given the similarity in FMT procedures across 
species, the GRAFT recommendations can also be 
used to guide FMT use in other species, and may 
offer guidance in human-animal transplantation if 
followed in combination with the recommenda-
tions presented by Walter et al. (2020).13
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While these guidelines provide the much-needed 
structure for preclinical FMT protocols, it is critical 
to emphasize that we do not aim to recommend 
what methods should be used, as different experi-
mental endpoints and research questions will 
clearly need a different methodological design (as 
previously discussed by Gheorghe et al.12). 
However, by consistently reporting the following 
set of guidelines, future studies will be more repro-
ducible and thus be more likely to generate clini-
cally relevant outcomes. Similarly, these guidelines 
will facilitate and structure the peer review process 
for preclinical FMT studies, which based on our 
analyses is poorly guided. We envisage that the 
GRAFT reporting recommendations will facilitate 
interpretation and experimental replication in 
Figure 4. Reproducibility index assessment. Each study was assessed against 10 criteria where 0 = not reported, 0.5 = reported with 
insufficient detail or 1 = reported with sufficient detail for replication. A) heatmap of individual scores for all N = 241 studies, B) total 
reproducibility index (RI) for all studies with median ± IQR. The median score was 6.5.
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a. Number of individual donors (per group) 
b. Detailed description of donor characteristics (see also ARRIVE Guidelines for animal donors), including but not limited to: 
- Species/strain of donors 
- Sex/gender of donors 
- Age and developmental stage of donors 
c. Details of control and experimental phenotypes (e.g. healthy vs disease phenotype) 
- Inclusion and exclusion criteria, with particular attention to factors relevant to the microbiome (e.g. diet, exercise) 
d. Details on housing and husbandry 
- Facility specifications (i.e. SPF/GF; If GF, include specifications of animal unit/isolator) 
- Co-housing vs single-housing 
- Arrangement of cages across racks (particularly with regards to separation of donor groups and separation from FMT 
recipient animals) 
- Bedding and chow
Sample collection process a. Type of sample (i.e. fecal pellet, intestinal/cecal content, mucosal scraping) 
b. Time of day of collection and details on minimization of circadian rhythm effects 
c. Animal handling during collection 
d. Details on sample collection methods (e.g. placing animal into clean cage until defecation or direct postmortem 
collection from cecum or intestines) 
- HUMAN DONORS: collection methods (e.g. normal defecation or directly from specific region of intestines during 
colonoscopy, medically indicated or otherwise)
Measures to minimize 
contamination
a. Aseptic procedures and protocols adopted during and after collection
Immediate storage 
conditions
a. Methods to minimize oxidative stress (i.e. use of transport medium) 
b. Immediate storage conditions (e.g. stored in reduced medium, snap frozen in liquid nitrogen, kept on ice or at ambient 
temperature etc.) 
c. Details on pooling of samples (if relevant) 
- Method of pooling (e.g. equal weight of initial sample from each donor prior to processing or equal volume of processed 
liquid) 
- Number of individual donors within each pool
Processing
Vehicle preparation a. Details of solution, including formulation, concentration, pH, temperature, volume 
b. Additives used to support microbial viability 
c. If de-oxygenated solution is used, specify method of de-oxygenation
Concentration a. Report using standardized units (mg/ml) 
- Avoid inaccurate units (e.g. pellets/ml)
Homogenization method a. Equipment used (e.g. vortex, Stomacher, autoclaved spatula) 
b. Intensity (using standardized units where possible) 
c. Time and temperature
Filtration method a. Method of filtration (e.g. gravity, centrifuge, strainer, stomacher bag) 
- Centrifuge: specify time, x g and temperature 
- Gravity: specify time and conditions (i.e. ambient, anaerobic, temperature) 
- Physical strainer/membrane: specify pore size or equivalent detail and filtration method
Anaerobic conditions a. Clearly state if/when anaerobic conditions were used 
b. Details of anaerobic conditions (i.e. chamber type, gas mix, temperature etc.)
Quality control a. Method used to assess FMT quality and composition prior to administration (e.g. plating, genomic sequencing) 
b. Outcome of quality assessment (e.g. CFU/ml, diversity index)
Storage
State of final product a. Define administered product as: 
- Fecal slurry (i.e. fecal contents with minimal filtration) – or - 
- Fecal supernatant/filtrate (i.e. microbial free) – or - 
- Microbial preparation (i.e. lyophilized or other)
Time in storage a. Time between preparation of final product and administration
Storage conditions a. Details of storage conditions between preparation and administration, including: 
- Volume per aliquot 
- Storage temperature 
- Duration of storage 
b. If fecal product is used fresh, this must be clearly stated with details including: 
- Short term storage conditions (i.e. on ice, fridge, room temperature, anaerobic chamber) 
- Time between preparation and administration
Freeze/thaw cycles a. Method of thawing fecal product prior to administration 








a. Number of recipient animals (per group) 
- If multiple animals receive FMT from the same donor (or pooled sample), this number should be reported for each donor, 
separately to the total 
b. Detailed description of recipient characteristics (see also ARRIVE Guidelines), including but not limited to: 
- Species/strain of recipients 
- Sex of recipients 
- Age and developmental stage of recipients 
c. Details on housing and husbandry 
- Facility specifications (i.e. SPF/GF; If GF, specifications of animal unit/isolator) 
- Co-housing vs single-housing 
- Arrangement of cages across racks (particularly with regards to separation of experimental groups and separation from 
FMT donor animals) 
- Bedding and chow
Host preparation techniques a. Methods of host preparation used prior to transplantation (e.g. antibiotic depletion, bowel cleansing, fasting) with relevant 
detail, including but not limited to: 
- Duration 
- Frequency (e.g. of changing antibiotic solution) 
- Specific treatment used (e.g. antibiotic names and concentrations) 
b. Preparation methods used in control group(s), with details as above 
c. Adverse events in response to preparation treatment (e.g. weight loss with antibiotics)
Confirmation of preparation 
success
a. Ideally, successful depletion of recipient microbiota should be confirmed through fecal analysis prior to FMT
Administration
Route and method of 
administration
a. Oral or rectal administration (or both) 
b. Method of administration (e.g. oral gavage, lavage, enema, coprophagia) 
c. Details on use of anesthesia or fasting prior to administration (particularly rectal) and coprophagic approaches (i.e. was 
additional FMT smeared on coat to improve uptake)
Volume and concentration a. Define in standard units for each individual FMT 
- Specify if absolute unit or relative to body weight of recipient
Time and frequency a. Time of day of administration 
b. Frequency of FMT, including total number and daily frequency (i.e. a total of 3 FMT by oral gavage at a frequency of 
1 per day, number of days between doses) 
c. Time between FMT administration and assessment of outcomes (i.e. disease status, behavioral change, microbiota 
composition etc.)
Control treatment a. Define treatment received by control animals (e.g. vehicle solution, autologous transplant, heat-killed FMT, FMT from 
control donor group) 
- Include control formulation, concentration, volume, time, and frequency as above
Confirmation
Engrafting/uptake of donor 
profile
a. Define how engraftment/uptake of the FMT procedure was confirmed (e.g. 16S rRNA/shotgun sequencing, fecal culture) 
- It is recommended that the same analysis be applied to the final FMT product administered to compare composition of 
donor and recipient 
b. Timing of sample collection for engraftment assessment relative to FMT administration and outcome assessments 
c. Details on sample collection methods, as for donor: 
- Time of day of collection 
- Handling during collection 
- Method: Placing animal into clean cage until defecation or direct postmortem collection from colon, cecum or other site
Durability/stability 
of donor profile
a. Particularly for lengthy experimental designs, it may be informative to analyze the recipient microbiota at multiple time- 
points after FMT administration to determine the long-term stability of the donor profile within the recipient
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future preclinical FMT studies, improving reprodu-
cibility, allowing better systematic review and meta- 
analysis, and future guidance on the most optimal 
methods to answer specific scientific questions.
Conclusions
This systematic review aimed to determine the 
most common protocols for FMT experiments in 
mice. Our key overarching finding was that many 
of the details required to reproduce these protocols 
were missing from the majority of papers, leading 
to the development of our minimum set of report-
ing guidelines. In the future, we urge researchers to 
clearly outline their protocols in order to provide 
transparency, increase reproducibility, and ulti-
mately enhance the chances of producing clinically 
relevant and translatable knowledge.
Key findings:
● 92.5% of studies included reported a positive 
outcome of FMT intervention
● Fecal slurries, containing both the microbiota 
and their metabolome, were the most common 
form of FMT product
● 91.7% of studies did not report on the use of 
anaerobic conditions during FMT product 
preparation
● Method of homogenization was not referred to 
in 33.6% of studies
● 49.4% did not report storage conditions for 
FMT product
● 21.4% of studies did not report on the sample 
size of the recipient group
● Antibiotic-induced depletion was the most 
common form of recipient preparation
● 5.3% of studies did not describe how the FMT 
was administered
● 19.9% did not report the volume of FMT 
administered
● FMT durability/uptake was not confirmed in 
22.1% of studies
● 88.4% of studies did not perform any quality 
control
● 40% of studies did not report on control FMT 
conditions
Figure 5. GRAFT framework for reproducible and transparent reporting.
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This systematic review aimed to answer the ques-
tion: “what FMT protocols are being used in pre-
clinical mouse models of health and disease?” FMT 
protocols were then used to define core aspects of 
preclinical FMT methodology and develop a set of 
minimum reporting standards.
Study design
The protocol for this systematic review was con-
ducted in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guidelines.29
Search strategy
We completed a comprehensive search using the 
electronic databases PubMed, Ovid Medline and 
Embase on June 30, 2020 (no date restrictions). 
The search parameters were tailored to each data-
base, and the full search string for each database 
can be found in the Supplementary Information. 
We searched for papers including fecal or cecal 
material transplant. In total, 1753 papers were iden-
tified from our database search.
Selection criteria
Two reviewers (KRS and HRW) conducted the 
initial literature search and removed duplicate arti-
cles. Following this, entries from prior to 2010 were 
removed to ensure only modern FMT protocols 
were included. Initially, abstracts and titles were 
screened using Covidence systematic review soft-
ware web program to assess eligibility (Veritas 
Health Innovation, Melbourne, Australia). 
Available at www.covidence.org). After this 
abstract screen, full-text articles were again assessed 
by the same reviewers. Two hundred and forty-one 
articles were selected for data extraction.
We aimed to retrieve only full-text, peer-reviewed, 
original experimental studies performed in mice. 
Studies must have been published in English. To be 
included in the review, studies must have completed 
a fecal or cecal microbiota transplant where mice 
were both the donor and the recipient.
Studies were excluded if they: used human or 
other non-mice microbial material for transplant, 
utilized GF mice as recipients or utilized a co- 
housing only approach to FMT. Secondary studies 
such as review papers, methodological protocols 
and conference abstracts were also excluded.
Data extraction and analysis
Seven reviewers (KRS, HRW, GHA, CBS, JS, MS, 
CC) independently extracted relevant informa-
tion from the selected papers using standard 
data collection templates. We extracted all avail-
able methodological data on FMT from the main 
paper or Supplementary Information. Key infor-
mation included: donor and recipient character-
istics (age, strain, antibiotic use), FMT 
preparation and storage methods, FMT admin-
istration (dosage, number of treatments, admin-
istration route) and use of quality control 
methods. To quantify the reproducibility of pre-
clinical FMT protocols included in our analysis, 
we developed a reproducibility index based on 
10 variables of preclinical FMT, irrespective of 
model or study goals. The criteria were as fol-
lows: buffer/vehicle, method of homogenization, 
filtration steps, storage (if applicable), concentra-
tion of final FMT product, pre-conditioning of 
the recipient, route of administration, volume 
administered, frequency of administration and 
the inclusion of anaerobic conditions. 
Reviewers marked each criterion as 0 = not 
reported, 0.5 = mentioned, 1 = mentioned with 
appropriate detail (to be able to effectively repli-
cate the study). Importantly, studies were 
assessed based on whether these parameters 
were reported, not for how they were performed. 
This index was not developed to provide 
a statistically comprehensive measure of repro-
ducibility, and as such there was not necessarily 
a linear relationship between the score and over-
all reproducibility of the study.
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